The historical rank and industry rank for Financiere de Tubize's Days Payable or its related term are showing as below:
STU:FTD'
s Days Payable Range Over the Past 10 Years
Min: 40.31 Med: 63.09 Max: 75.1
Current: 49.7
During the past 13 years, Financiere de Tubize's highest Days Payable was 75.10. The lowest was 40.31. And the median was 63.09.
STU:FTD's Days Payable is ranked worse than 68.09% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs STU:FTD: 49.70
Financiere de Tubize's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Financiere de Tubize Days Payable Related Terms
Financiere de Tubize Days Payable Historical Data
* Premium members only.
The historical data trend for Financiere de Tubize's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FTD vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Financiere de Tubize's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Financiere de Tubize Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Financiere de Tubize's Days Payable distribution charts can be found below:
* The bar in red indicates where Financiere de Tubize's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Financiere de Tubize's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Financiere de Tubize (STU:FTD) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Financiere de Tubize and its competitors. Over the past decade, Financiere de Tubize's Days Payable has ranged from 40.31 to 75.10. According to the industry distribution chart, Financiere de Tubize ranks #478 out of 702 companies in the Biotechnology industry, placing it in the top 68.1%.
Is Financiere de Tubize's Days Payable too high?
Financiere de Tubize's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 40.31 to a high of 75.10. Based on the distribution chart, Financiere de Tubize ranks #478 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Financiere de Tubize has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Financiere de Tubize's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Financiere de Tubize ranks #478 out of 702 companies for Days Payable. This places Financiere de Tubize in the lower half of its industry. The industry median Days Payable is 113.56. Historically, Financiere de Tubize's own Days Payable has ranged from 40.31 to 75.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Financiere de Tubize and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Financiere de Tubize's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Financiere de Tubize stock overvalued right now?
Financiere de Tubize (STU:FTD) has a current Days Payable of 0.00. The current Days Payable is 0.00. Financiere de Tubize's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Financiere de Tubize (STU:FTD), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a world-wide biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Majority of its sales revenue is derived from its neurology products, followed by its immunology products. The company's plan focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
39GF Score
Get the complete analysis for STU:FTD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FTD has been successfully added to your 
